[Breakthrough T1D](https://www.breakthrought1d.org)

November 2026 (Letter of Intent/LOI, projected)

Up to $3,000,000 total for up to 3 years (Strategic Research Agreement); budget must match scope—smaller projects considered.

Supports research to clarify the clinical significance of insulin dosing in type 1 diabetes, focusing on how insulin dose relates to meaningful outcomes and patient care.

--- ## Description This grant opportunity from Breakthrough T1D supports research studies that investigate the clinical significance of insulin dose in type 1 diabetes (T1D). The primary aim is to clarify how insulin dosing metrics and changes correspond to clinically meaningful outcomes and patient-relevant endpoints, enhancing the interpretation and utility of insulin dose as a clinical measure in T1D care, research, and possibly regulatory contexts. Projects are encouraged that will improve the understanding of insulin dose to inform treatment decisions and advance T1D management. --- ## Due Dates - Letter of Intent (LOI) deadline (anticipated): November 2026 *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - Maximum funding: Up to $3,000,000 total for up to 3 years under the Strategic Research Agreement (SRA) mechanism. - Indirect costs: Up to 10% of direct costs (for SRA). - The actual amount awarded will depend on project scope, aims, and justification; smaller projects are encouraged and considered. - Industry Discovery & Development Partnership (IDDP) applications (for for-profit entities) require matching funds and do not allow indirect costs. --- ## Eligibility - Applicants must hold an M.D., D.O., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility. - Eligible institutions include domestic and foreign non-profit organizations, public and private universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government. - For-profit organizations may apply under the IDDP mechanism and must provide matching funds. - There are no citizenship restrictions. - Breakthrough T1D encourages applications from diverse backgrounds, including underrepresented groups. --- ## Application Process 1. **Review the RFA and Grant Handbook:** Read the [official RFA](https://www.breakthrought1d.org/wp-content/uploads/2025/10/Insulin-Dose-RFA-3.0_Revised.pdf) and [Grant Handbook](https://www.breakthrought1d.org/granthandbook/) for specific requirements, eligibility, and guidance. 2. **Submit Letter of Intent (LOI):** Prepare and submit an LOI via the [RMS360 portal](https://breakthrought1d.smartsimple.us/) by the anticipated deadline. Use the LOI template provided in the RFA. 3. **Full Proposal (by invitation):** If your LOI is approved, you will be invited to submit a full proposal using the RMS360 system and relevant templates. 4. **Review Process:** Applications are evaluated for significance, innovation, approach, relevance to T1D, environment, and alignment with Breakthrough T1D’s strategic priorities. 5. **Compliance:** Proposals involving human subjects or animals must comply with all relevant ethical and regulatory standards as outlined in the Grant Handbook. --- ## Additional Information - Projects must address how insulin dose can be interpreted as a clinically meaningful outcome. - Collaborative and multidisciplinary approaches are encouraged. - Applicants are expected to justify the choice of endpoints and study design. - For-profit applicants (IDDP) must discuss scope and budget with Breakthrough T1D staff prior to submission and provide matching resources. - All proposals must be submitted through the [RMS360 system](https://breakthrought1d.smartsimple.us/). --- ## External Links - [Main Breakthrough T1D Funding Opportunities Page](https://www.breakthrought1d.org/explore-research/funding-opportunities/) - [Grant Handbook](https://www.breakthrought1d.org/granthandbook/) - [Insulin Dose RFA (PDF)](https://www.breakthrought1d.org/wp-content/uploads/2025/10/Insulin-Dose-RFA-3.0_Revised.pdf) - [RMS360 Application Portal](https://breakthrought1d.smartsimple.us/) - [Breakthrough T1D Research Strategy](https://www.breakthrought1d.org/explore-research/research-strategy/) --- ## Contact Information | Purpose | Contact Person | Email | |-----------------------------------------------|-------------------------|--------------------------------------| | Strategic/scientific inquiries | Courtney Ackeifi, PhD | cackeifi@BT1D.org | | Administrative questions | Sanjukta Mukerjee, PhD | smukerjee@BT1D.org | | General/pre-award support | Pre-Award Support Team | preawardsupport@breakthrought1d.org | | Web contact form | Breakthrough T1D | [Contact Us](https://www.breakthrought1d.org/contact-us/) | ---

Studies Assessing The Clinical Meaningfulness Of Insulin Dose In Type 1 Diabetes

Sign in to see full grant listing